Reed Jobs Prefers Talking About Curing Cancer Over His Famous Surname

When we first interviewed Reed Jobs at TechCrunch Disrupt three years ago, his venture firm Yosemite was just a newborn in a biotech landscape still reeling from the pandemic’s fallout. Today, the company has expanded to a 17‑person team and is navigating a wave of blockbuster drugs that are about to lose patent protection, opening a flood of opportunities for innovative therapies.

Jobs emphasizes how artificial intelligence has shifted from a niche curiosity to a core component of Yosemite’s operations. “I didn’t expect Yosemite to be moving this fast,” he admits, noting that AI now drives everything from target identification to early‑stage clinical trial design. Machine‑learning models sift through massive genomic datasets, predict protein structures, and flag promising compound candidates far quicker than traditional methods.

While his last name inevitably draws headlines, Reed is quick to say his priority lies elsewhere. “I’d rather talk about curing cancer than my surname,” he explains, underscoring a personal mission that outweighs the legacy of his famous father. This focus shapes Yosemite’s investment thesis: back projects that leverage AI to accelerate drug discovery and address the looming patent cliff affecting many high‑revenue medicines.

The firm’s rapid scaling has attracted attention from both venture capitalists and big‑pharma partners eager to plug the upcoming gap in the market. By combining cutting‑edge computational tools with a deep understanding of disease biology, Yosemite aims to shorten development timelines and bring effective treatments to patients faster.

Looking ahead, Jobs plans to launch additional clinical programs, using AI to refine trial cohorts and improve success rates. His vision positions Yosemite not just as a fund but as an active engine for change in the fight against cancer, proving that the name on the door matters far less than the breakthroughs happening inside.

Source: TechCrunch

ETİKETLER